Peijia Medical-B (09996) rose more than 6%, as of press time, rose 6.18%, reported HKD 2.75, with a turnover of 10.8212 million Hong Kong dollars.
According to the WiseNews App, Peijia Medical-B (09996) rose more than 6%, as of press time, rose 6.18%, reported HKD 2.75, with a turnover of 10.8212 million Hong Kong dollars.
On the news front, Peijia Medical will release its mid-term performance for 2024 on August 23. The Company previously announced that its revenue for the first six months ending June was approximately RMB 0.29 billion-0.31 billion, a year-on-year increase of 28.9%-37.8%. This is mainly due to the accelerated commercialization of the endovascular aortic valve replacement products, further expanding the Group's market share, the significant increase in sales of the Group's spring coil products due to the implementation of centralized volume-based procurement in the provinces where it won bids, and the sale of about 1.91% of JenaValve by the Company, with an expected pre-tax sales income of $5.1 million.
In addition, Peijia Medical's partner, JenaValve, has reached an agreement with Edwards Lifesciences (NYSE: EW, referred to as “Edwards”), a giant in the US medical device industry, under which Edwards Lifesciences will acquire all the shares of JenaValve. After the completion of the transaction, Peijia Medical will continue to have the exclusive rights to the JenaValve Trilogy THV system in Greater China.